Achieving long-term cure through improved treatment: this is the aim of the new CHIP-AML22 (Master Protocol) trial. It is now open to children and adolescents with Acute Myeloid Leukaemia at SPOG member hospitals.
SPOG has just opened the CHIP-AML22 (Master Protocol) clinical trial at its first member hospitals. The study is intended for children and adolescents with Acute Myeloid Leukaemia (AML). Leukaemias are malignant diseases of blood-forming cells in the bone marrow.
Developing better first-line treatment
Although current treatment for AML achieves good outcomes, not all young patients respond to the first-line treatment. In some, the disease returns later and the prospects of cure are less favourable. This is where the CHIP-AML22 (Master Protocol) clinical trial comes in: it aims to prevent treatment failure or relapse by improving first-line treatment. This international clinical trial is designed to allow as many young patients as possible to participate.
Personalised treatment and innovative medicinal products
CHIP-AML22 (Master Protocol) is a complex treatment-optimisation study. The therapy used in the study is based on current standard treatment but also includes new elements. Researchers are examining, among other factors, the genetic characteristics of leukaemia cells at diagnosis. Based on these findings, patients will be assigned to different treatment groups within the clinical trial. In this way, treatment is more precisely tailored to each patient, including the use of innovative medicinal products. The clinical trial aims to deliver better treatment that achieves long-term cure with fewer side effects.
Further information: CHIP-AML22 (Master Protocol)
Brigitte Casanova
Brigitte Casanova supports SPOG communication projects; as a Germanist, she complements the science-oriented team at the Coordination Center.
More articles from Brigitte Casanova 
